Answer
Dovato is contraindicated with fampridine because its dolutegravir component inhibits renal OCT2 and MATE1 transporters and may increase fampridine concentrations, while fampridine is an OCT2 substrate with a narrow therapeutic window.
Sources for this answer
- Dovato 50 mg/300 mg film-coated tabletsViiV Healthcare UK Ltd · emc · SmPC §4.3 Contraindications · Version 17Document updated
- Dovato 50 mg/300 mg film-coated tablets